UCB U.S. News | UCB

UCB's Global Corporate Website

Welcome to UCB in the United States

Categories

Archives

2024
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2023
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2022
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2021
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January

Oct

15

Powering the dreams of people impacted by myasthenia gravis (MG)

Read More Share:

|

|

Oct

15

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Read More Share:

|

|

Oct

14

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Read More Share:

|

|

Oct

11

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:

|

|